Payment overview · 2025
General Payments
$866.62
14 reported records · 9 companies
Healthcare provider profile · identity verified
Shane Jeffers, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HILLIARD, OH · NPI 1053707893
Verified facts
What the public records show
CMS Open Payments records show Shane Jeffers, M.D. received $866.62 in general payments during 2025 across 14 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $369.21 | 42.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.13 | 17.0% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $135.00 | 15.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.39 | 14.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.19 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.66 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.90 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.56 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $866.62 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $369.21 | 4 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $129.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.39 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $10.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 148 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
148 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 222 |
| Lisinopril | Lisinopril | 575 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 155 |
| Losartan Potassium | Losartan Potassium | 430 | 124 |
| Gabapentin | Gabapentin | 362 | 88 |
| Meloxicam | Meloxicam | 308 | 94 |
| Omeprazole | Omeprazole | 257 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 231 | 81 |
| Baclofen | Baclofen | 225 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 198 | 68 |
| Furosemide | Furosemide | 168 | 66 |
| Bupropion Xl | Bupropion Hcl | 159 | 55 |
| Prednisone | Prednisone | 159 | 131 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 148 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 141 | 46 |
| Alendronate Sodium | Alendronate Sodium | 137 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 32 |
| Metformin Hcl | Metformin Hcl | 133 | 47 |
| Simvastatin | Simvastatin | 121 | 47 |
| Trazodone Hcl | Trazodone Hcl | 121 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 57 |
| Ozempic | Semaglutide | 112 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 43 |
| Eliquis | Apixaban | 106 | 37 |
| Carvedilol | Carvedilol | 103 | 35 |
| Jardiance | Empagliflozin | 102 | 37 |
| Glipizide Er | Glipizide | 98 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 36 |
| Metformin Hcl Er | Metformin Hcl | 96 | 34 |
| Spironolactone | Spironolactone | 92 | 35 |
| Sertraline Hcl | Sertraline Hcl | 91 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 30 |
| Potassium Chloride | Potassium Chloride | 88 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 31 |
| Topiramate | Topiramate | 84 | 22 |
| Buspirone Hcl | Buspirone Hcl | 81 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 28 |
| Montelukast Sodium | Montelukast Sodium | 70 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 26 |
| Allopurinol | Allopurinol | 63 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 22 |
| Famotidine | Famotidine | 62 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 62 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 21 |
| Meclizine Hcl | Meclizine Hcl | 56 | 25 |
| Chlorthalidone | Chlorthalidone | 53 | 25 |
| Azithromycin | Azithromycin | 52 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 35 |
| Mirtazapine | Mirtazapine | 48 | 17 |
| Pregabalin | Pregabalin | 45 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Finasteride | Finasteride | 40 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Mounjaro | Tirzepatide | 38 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Atenolol | Atenolol | 35 | 13 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 28 |
| Methocarbamol | Methocarbamol | 34 | 11 |
| Trulicity | Dulaglutide | 34 | 14 |
| Farxiga | Dapagliflozin Propanediol | 33 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 16 |
| Alprazolam | Alprazolam | 32 | 13 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | 11 |
| Fenofibrate | Fenofibrate | 29 | 11 |
| Lamotrigine | Lamotrigine | 29 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 12 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Glipizide | Glipizide | 21 | 11 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Estradiol | Estradiol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Nystatin | Nystatin | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $866.62 · 14 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Descovy, Dexcom G6 Transmitter, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error